The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Overcoming cell size escape from tumor treating fields using a varying frequency treatment paradigm in vitro.
Rosa S. Schneiderman
Employment or Leadership Position - Novocure
Moshe Giladi
Employment or Leadership Position - Novocure
Yaara Porat
Employment or Leadership Position - Novocure
Mijal Munster
Employment or Leadership Position - Novocure
Uri Weinberg
Employment or Leadership Position - Novocure
Eilon David Kirson
Employment or Leadership Position - Novocure
Yoram Palti
Employment or Leadership Position - Novocure
Stock Ownership - Novocure